|
9.20 - 9.30 |
Welcome and Introduction |
|
Ottilia Saxl, CEO, The Institute of Nanotechnology
|
Plenary session
The Promise of Nanomedicine
Chair: Prof. Shervanthi Homer Vanniasinkam, Consultant Vascular Surgeon, Leeds General Infirmary Professor of Translational Vascular Medicine, Leeds Medical School UK |
9.30 - 9.55 |
|
|
Prof. Dr J W (Hans) Hofstraat, Vice President Philips Research, Healthcare Strategic Partnerships
|
10.00 - 10.25 |
|
|
Dr Tar Choon Aw, Professor of Chemical Pathology, Monash University School of Medicine, Malaysia
|
10.30 - 10.55 |
Refreshments |
| |
|
Session 1:
Tissue engineering and regenerative medicine
Chair: Professor Jörg Vienken, Vice President, Fresenius Medical Care, Germany
|
11.00 - 11.20 |
|
|
Prof. Jörg Vienken, Vice President, Fresenius Medical Care |
11.25 -11.45 |
|
|
Nicholas Sleep, CEO Magnecell Ltd
|
11.50 - 12.10 |
|
|
Dr Nick Skaer, CEO, Oxford Biomaterials
|
12.15 - 12.35 |
|
|
Dr Eliane Schutte, Signifix
|
12.40-13.55 |
Lunch |
| |
|
Session 2:
Drug Delivery and Pharmaceutical Development
Chair: Dr. Richard Moore, Manager, Nanomedicine and Lifesciences, Institute of Nanotechnology
|
|
|
|
Prof. Clive Washington, Principal Scientist, Astra Zeneca |
14.30 - 14.50 |
|
|
Prof. Amarnath Maitra, University of Delhi
|
|
|
|
Professor Peter Ghazal, University of Edinburgh Medical School, UK
|
15.20 - 15.45 |
Refreshments |
| |
|
15.50 - 16.10 |
|
|
Dr Daniel E Lynch, Technical Director, Exilica Ltd
|
|
|
|
Karsten Hipler, CEO, ImuThes
|
|
|
18.30 - 20.00
|
Public Debate: 'Nanomedicine… hype? Or a real revolution in healthcare?'
|
|
|
9.20 - 9.30 |
NanoMedNet - an overview |
| |
Richard Moore, Nanomedicine and Lifesciences, Institute of Nanotechnology, UK
|
Plenary session:
Medical Nanotechnology- Challenges and Opportunities
Chair: Dr Leonard Fass, GE Healthcare, UK |
9.30 - 9.55 |
Nanotech - Cutting through the hype. A realistic business case for pharma |
|
Dr Thomas Keller, Director - World Wide Applied Technology, GlaxoSmithKline
|
| 10.00 - 10.25 |
Medical Nanotechnology: A Clinician-Scientist's Perspective |
| |
Professor Shervanthi Homer Vanniasinkam, Consultant Vascular Surgeon, Leeds General
Infirmary Professor of Translational Vascular Medicine, Leeds Medical School, UK
|
| 10.30 - 10.55 |
Refreshments
|
| |
|
|
Session 3:
Novel Devices, Nanosensors and Diagnostics
Chair: Professor Michael Horton, Bone and Mineral Centre and Sackler Institute for Musculoskeletal Research, Executive Council member of LCN, London, UK
|
11.00 - 11.20 |
Highly integrated Lab-on-Chip platform for multiplexed molecular diagnostics |
| |
Dr. Michele Palmieri, R&D Manager, Lab-on-Chip Program, Microfluidics Division, STMicroelectronics |
11.25 - 11.45 |
|
| |
Dr. Gerry Ronan, CEO, Farfield Scientific, UK
|
11.50 - 12.10 |
|
|
Prof Lars Montelius, Dean of the Physics Department & Head of Exploratory Nanotechnology Group, University of Lund
|
12.15 - 13.30 |
Lunch |
|
Session 4:
Investing in NanoMedicine: Strategy and Vision for the Future
Chair: Rhian Granleese, Marks & Clerk
|
13.35 - 14.00 |
|
|
Renzo Tomellini, Head of the Nanosciences and Nanotechnologies Unit, European Commision
|
14.05 - 14.30 |
|
|
Robert Geertsma, Centre for Biological
Medicines and Medical Technology, National
Institute for Public Health and the Environment
(RIVM), Bilthoven, NL
|
14.35 - 15.00 |
|
|
Dr Nicola Baily, Business Analyst,
Technology Transfer, The Wellcome Trust
|
15.05 - 15.30 |
|
|
Ogan Gurel, Managing Director, XRoads Solutions Group, LLC
|
15.35 - 15.45 |
|
15..50 |
|
Updated: 23/11/07 |
